PCN49 Biosimilar Trastuzumab Mono- and Pertuzumab Combination Therapy in Metastatic Breast Cancer: Cost Efficiency and Expanded Access Modeling
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.141
https://www.valueinhealthjournal.com/article/S1098-3015(21)00358-2/fulltext
Title :
PCN49 Biosimilar Trastuzumab Mono- and Pertuzumab Combination Therapy in Metastatic Breast Cancer: Cost Efficiency and Expanded Access Modeling
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00358-2&doi=10.1016/j.jval.2021.04.141
First page :
Section Title :
Open access? :
No
Section Order :
10722